WKWillem-Jan Keune

Willem-Jan Keune

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Willem-Jan Keune has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Nullin Divecha

    Inositide Laboratory, School of Biological Sciences, University of Southampton, SO17 1BJ, Southampton, UK

    9 shared publications
  • David R. Jones

    Oncology iMED, AstraZeneca, Alderley Park, Macclesfield SK10 4TF, UK

    8 shared publications
  • Yvette Bultsma

    Authors' Affiliations: 1The CRUK Inositide Laboratory; 2Breakthrough Breast Cancer Research Unit; 3Leukaemia Biology, Inositide Group Cancer Research UK Manchester Institute, The University of Manchester, Manchester; 4Applied Bioinformatics of Cancer, University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom; and 5Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital Malmö, Malmö, Sweden

    6 shared publications
  • Anastassis Perrakis

    The Netherlands Cancer Institute

    5 shared publications
  • Allan John Bell Watson

    EaStCHEM School of Chemistry University of St Andrews St Andrews UK

    2 shared publications
  • Craig Jamieson

    Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow, G1 1XL

    2 shared publications

Latest Publications

  • Open Access

    Lysophosphatidic acid produced by Autotaxin acts as an allosteric modulator of its catalytic efficiency

    by Fernando Salgado-Polo, Alexander Fish, Minos-Timotheos Matsoukas, Tatjana Heidebrecht, Willem-Jan Keune, Anastassis Perrakis

    Autotaxin is a secreted phosphodiesterase that converts lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA). LPA controls key cellular responses such as migration, proliferation and survival, implicating ATX-LPA signalling in various (patho)physiological processes and establishing it as a drug target. ATX structural and functional studies have revealed an orthosteric and an allosteric site, the “pocket” and the “tunnel”. Here, we revisit the kinetics of the ATX catalytic cycle in light of allosteric regulation, dissecting the different steps and pathways that lead to LPC hydrolysis. Consolidating all experimental kinetics data to a comprehensive catalytic model supported by molecular modelling simulations, suggests a positive feedback mechanism, regulated by the abundance of the LPA products activating hydrolysis of different LPC species. Our results complement and extend current understanding of ATX hydrolysis in light of the allosteric regulation by produced LPA species, and have implications for the design and application of orthosteric and allosteric ATX inhibitors.


  • Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators

    by Willem-Jan Keune, Frances Potjewyd, Tatjana Heidebrecht, Fernando Salgado-Polo, Simon J. F. Macdonald, Lakshman Chelvarajan, Ahmed Abdel Latif, Sony Soman, Andrew J. Morris, Allan J. B. Watson, et al.

    Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.


  • Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode

    by Lisa M. Miller, Willem-Jan Keune, Diana Castagna, Louise C. Young, Emma L. Duffy, Frances Potjewyd, Fernando Salgado-Polo, Paloma Engel García, Dima Semaan, John M. Pritchard, et al.

    Autotaxin (ATX) is a secreted enzyme responsible for the hydrolysis of lysophosphatidylcholine (LPC) to the bioactive lysophosphatidic acid (LPA) and choline. The ATX-LPA signaling pathway is implicated in cell survival, migration, and proliferation; thus, the inhibition of ATX is a recognized therapeutic target for a number of diseases including fibrotic diseases, cancer, and inflammation, among others. Many of the developed synthetic inhibitors for ATX have resembled the lipid chemotype of the native ligand; however, a small number of inhibitors have been described that deviate from this common scaffold. Herein, we report the structure–activity relationships (SAR) of a previously reported small molecule ATX inhibitor. We show through enzyme kinetics studies that analogues of this chemotype are noncompetitive inhibitors, and by using a crystal structure with ATX we confirm the discrete binding mode.


  • Structural snapshots of the catalytic cycle of the phosphodiesterase Autotaxin

    by Jens Hausmann, Willem-Jan Keune, Agnes L. Hipgrave Ederveen, Leonie van Zeijl, Robbie P. Joosten, Anastassis Perrakis


  • Open Access

    Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling

    by Willem-Jan Keune, Jens Hausmann, Ruth Bolier, Dagmar Tolenaars, Andreas Kremer, Tatjana Heidebrecht, Robbie P. Joosten, Manjula Sunkara, Andrew J. Morris, Elisa Matas-Rico, et al.

    Autotaxin (ATX) generates the lipid mediator lysophosphatidic acid (LPA). ATX-LPA signalling is involved in multiple biological and pathophysiological processes, including vasculogenesis, fibrosis, cholestatic pruritus and tumour progression. ATX has a tripartite active site, combining a hydrophilic groove, a hydrophobic lipid-binding pocket and a tunnel of unclear function. We present crystal structures of rat ATX bound to 7α-hydroxycholesterol and the bile salt tauroursodeoxycholate (TUDCA), showing how the tunnel selectively binds steroids. A structure of ATX simultaneously harbouring TUDCA in the tunnel and LPA in the pocket, together with kinetic analysis, reveals that bile salts act as partial non-competitive inhibitors of ATX, thereby attenuating LPA receptor activation. This unexpected interplay between ATX-LPA signalling and select steroids, notably natural bile salts, provides a molecular basis for the emerging association of ATX with disorders associated with increased circulating levels of bile salts. Furthermore, our findings suggest potential clinical implications in the use of steroid drugs.


  • PIP4K and the role of nuclear phosphoinositides in tumour suppression

    by Roberta Fiume, Yvette Stijf-Bultsma, Zahid H. Shah, Willem Jan Keune, David R. Jones, Julian Georg Jude, Nullin Divecha


  • Low PIP4K2B Expression in Human Breast Tumors Correlates with Reduced Patient Survival: A Role for PIP4K2B in the Regulation of E-Cadherin Expression

    by Willem-Jan Keune, Andrew H. Sims, David R. Jones, Yvette Bultsma, James T. Lynch, Karin Jirström, Goran Landberg, Nullin Divecha

    Phosphatidylinositol-5-phosphate (PtdIns5P) 4-kinase β (PIP4K2B) directly regulates the levels of two important phosphoinositide second messengers, PtdIns5P and phosphatidylinositol-(4,5)-bisphosphate [PtdIns(4,5)P2]. PIP4K2B has been linked to the regulation of gene transcription, to TP53 and AKT activation, and to the regulation of cellular reactive oxygen accumulation. However, its role in human tumor development and on patient survival is not known. Here, we have interrogated the expression of PIP4K2B in a cohort (489) of patients with breast tumor using immunohistochemical staining and by a meta-analysis of gene expression profiles from 2,999 breast tumors, both with associated clinical outcome data. Low PIP4K2B expression was associated with increased tumor size, high Nottingham histological grade, Ki67 expression, and distant metastasis, whereas high PIP4K2B expression strongly associated with ERBB2 expression. Kaplan–Meier curves showed that both high and low PIP4K2B expression correlated with poorer patient survival compared with intermediate expression. In normal (MCF10A) and tumor (MCF7) breast epithelial cell lines, mimicking low PIP4K2B expression, using short hairpin RNA interference-mediated knockdown, led to a decrease in the transcription and expression of the tumor suppressor protein E-cadherin (CDH1). In MCF10A cells, knockdown of PIP4K2B enhanced TGF-β–induced epithelial to mesenchymal transition (EMT), a process required during the development of metastasis. Analysis of gene expression datasets confirmed the association between low PIP4K2B and low CDH1expression. Decreased CDH1 expression and enhancement of TGF-β–induced EMT by reduced PIP4K2B expression might, in part, explain the association between low PIP4K2B expression and poor patient survival. Cancer Res; 73(23); 6913–25. ©2013 AACR.


  • Collaboration of AMPK and PKC to induce phosphorylation of Ser413 on PIP5K1B resulting in decreased kinase activity and reduced PtdIns(4,5)P2 synthesis in response to oxidative stress and energy restriction

    by Iman van Den Bout, David R. Jones, Zahid H. Shah, Jonathan R. Halstead, Willem-Jan Keune, Shabaz Mohammed, Clive S. D’sAntos, Nullin Divecha

    The spatial and temporal regulation of the second messenger PtdIns(4,5)P2 has been shown to be crucial for regulating numerous processes in the cytoplasm and in the nucleus. Three isoforms of PIP5K1 (phosphatidylinositol 4-phosphate 5-kinase), A, B and C, are responsible for the regulation of the major pools of cellular PtdIns(4,5)P2. PIP5K1B is negatively regulated in response to oxidative stress although it remains unclear which pathways regulate its activity. In the present study, we have investigated the regulation of PIP5K1B by protein phosphorylation. Using MS analysis, we identified 12 phosphorylation sites on PIP5K1B. We developed a phospho-specific antibody against Ser413 and showed that its phosphorylation was increased in response to treatment of cells with phorbol ester, H2O2 or energy restriction. Using inhibitors, we define a stress-dependent pathway that requires the activity of the cellular energy sensor AMPK (AMP-activated protein kinase) and PKC (protein kinase C) to regulate Ser413 phosphorylation. Furthermore, we demonstrate that PKC can directly phosphorylate Ser413in vitro. Mutation of Ser413 to aspartate to mimic serine phosphorylation decreased both PIP5K1B activity in vitro and PtdIns(4,5)P2 synthesis in vivo. Our studies show that collaboration between AMPK and PKC dictates the extent of Ser413 phosphorylation on PIP5K1B and regulates PtdIns(4,5)P2 synthesis.


  • PtdIns5P and Pin1 in oxidative stress signaling

    by Willem-Jan Keune, David R. Jones, Nullin Divecha


  • Open Access

    PtdIns5 P is an oxidative stress‐induced second messenger that regulates PKB activation

    by David R. Jones, Rebecca Foulger, Willem‐Jan Keune, Yvette Bultsma, Nullin Divecha

    Oxidative stress initiates signaling pathways, which protect from stress‐induced cellular damage, initiate apoptosis, or drive cells into senescence or into tumorigenesis. Oxidative stress regulates the activity of the cell survival factor PKB, through the regulation of PtdIns(3,4,5) P 3 synthesis. Whether oxidative stress regulates other phosphoinositides to control PKB activation is not clear. Here we show that PtdIns5 P is a redox‐regulated second messenger. In response to hydrogen peroxide (H 2 O 2 ), we measured an increase in PtdIns5 P in cells derived from human osteosarcoma, U2OS (5‐fold); breast tumors, MDA‐MB‐468 (2‐fold); and fibrosarcoma, HT1080 (3‐fold); and in p53‐null murine embryonic fibroblasts (8‐fold). In U2OS cells, the increase in H 2 O 2 ‐dependent PtdIns5 P did not require mTOR, PDK1, PKB, ERK, and p38 signaling or PIKfyve, a lipid kinase that increases PtdIns5 P in response to osmotic and oncogenic signaling. A reduction in H 2 O 2 ‐in‐duced PtdIns5 P levels by the overexpression of PIP4K revealed its role in PKB activation. Suppression of H 2 O 2 ‐induced PtdIns5 P generation reduced PKB activation and, surprisingly, reduced cell sensitivity to growth inhibition by H 2 O 2 . These data suggest that inhibition of PIP4K signaling might be useful as a novel strategy to increase the susceptibility of tumor cells to therapeutics that function through increased oxidative stress.—Jones, D. R., Foulger, R., Keune, W.‐J., Bultsma, Y., Divecha, N. PtdIns5 P is an oxidative stress‐induced second messenger that regulates PKB activation. FASEB J. 27, 1644–1656 (2013). www.fasebj.org